{"id":62231,"date":"2026-04-22T00:51:15","date_gmt":"2026-04-21T22:51:15","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms\/"},"modified":"2026-04-22T00:51:15","modified_gmt":"2026-04-21T22:51:15","slug":"understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms\/","title":{"rendered":"Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2026 Apr 20;100:102770. doi: 10.1016\/j.coi.2026.102770. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, microvascular disease, pregnancy morbidity, or non-thrombotic manifestations in patients with antiphospholipid antibodies. The mechanistic differentiation of these clinical phenotypes has diagnostic and therapeutic implications. Across APS phenotypes, a shared set of effector mechanisms are: a) endothelial activation and dysfunction; b) platelet, monocyte, and neutrophil activation; c) complement activation; and d) downstream coagulation system activation. Taken together, these shared mechanisms provide a unifying framework for understanding how APS produces an immunothrombotic environment as well as distinct, yet overlapping, clinical domains. In this review article, we apply this framework to: a) macrovascular (thrombotic) APS; b) microvascular APS; c) obstetric APS; d) non-thrombotic aPL manifestations; and d) catastrophic APS, highlighting phenotype-specific clinical and mechanistic nuances while emphasizing convergent pathways.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013510\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20260421185114&amp;v=2.19.0.post6+133c1fe\">42013510<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2026.102770\">10.1016\/j.coi.2026.102770<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2026 Apr 20;100:102770. doi: 10.1016\/j.coi.2026.102770. Online ahead of print. ABSTRACT Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, microvascular disease, pregnancy morbidity, or non-thrombotic manifestations in patients with antiphospholipid antibodies. The mechanistic differentiation of these clinical phenotypes has diagnostic and therapeutic implications. Across APS phenotypes, a shared set of &#8230; <a title=\"Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/understanding-antiphospholipid-syndrome-clinical-phenotypes-with-the-guidance-of-antiphospholipid-antibody-related-pathogenic-mechanisms\/\" aria-label=\"Read more about Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-62231","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62231"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62231\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}